Small cell lung cancer (SCLC) is an aggressive form of lung cancer that grows and spreads faster than any other type of lung cancer. It accounts for about 10 to 15 percent of all lung cancers and is almost exclusively linked to cigarette smoking. Unlike the more common non-small cell type, SCLC tends to originate in the central airways of the lungs and has often already spread by the time it’s found.
Where Small Cell Lung Cancer Comes From
SCLC develops from specialized hormone-producing cells in the lung called neuroendocrine cells. These cells normally help regulate airflow and blood supply in the lungs. When they turn cancerous, they produce tumors made up of small, densely packed cells with very little internal structure, which is where the name comes from.
What makes SCLC so dangerous is its growth rate. The cells divide at an extraordinary pace, averaging about 80 cell divisions per small tissue sample, compared to far fewer in slower-growing cancers. More than half of the cells in a typical SCLC tumor are actively dividing at any given time. This rapid multiplication is why the cancer spreads so quickly and why tumors often outgrow their own blood supply, leaving large areas of dead tissue within the tumor itself.
Smoking and Other Risk Factors
About 80 percent of all lung cancer deaths are tied to smoking, and that number is likely even higher for SCLC specifically. It is rare for someone who has never smoked to develop this cancer. The relationship between smoking and SCLC is one of the strongest of any cancer-carcinogen link in medicine.
Beyond smoking, secondhand smoke is the third most common cause of lung cancer in the United States. Radon, a colorless, odorless radioactive gas that seeps up from soil and rock into homes, ranks as the second leading cause overall and the leading cause among nonsmokers. Workplace exposures to asbestos, arsenic, cadmium, chromium compounds, and diesel exhaust also raise risk, though all of these pale in comparison to the effect of tobacco.
Symptoms and How They Appear
SCLC that hasn’t spread rarely causes noticeable symptoms, which is part of why it’s so often caught late. When symptoms do appear, they typically include a persistent cough that worsens over time, chest pain, difficulty breathing, wheezing, coughing up blood, hoarseness, unexplained weight loss, fatigue, and loss of appetite. Some people notice facial swelling or visibly swollen neck veins, which happen when the tumor presses on the large vein that carries blood from the head back to the heart.
Because SCLC grows so rapidly, symptoms can seem to come on suddenly. A cough that was mild a few weeks ago may become severe in a short window. This quick progression is one of the features that often distinguishes SCLC from the slower-developing non-small cell type.
Paraneoplastic Syndromes
SCLC has an unusual trait: the cancer cells can produce hormones and antibodies that cause problems far from the lungs. These are called paraneoplastic syndromes, and they sometimes appear before the cancer itself is detected.
The most common is a condition where the body retains too much water because the tumor secretes a hormone that tells the kidneys to hold onto fluid. This affects 10 to 45 percent of SCLC patients at some point during their illness and can cause confusion, nausea, and dangerously low sodium levels. Another 1 to 5 percent of patients develop a syndrome where excess cortisol floods the body, causing weight gain, high blood sugar, and muscle weakness.
On the neurological side, about 1 to 3 percent of patients develop Lambert-Eaton myasthenic syndrome, a condition where the immune system attacks the connections between nerves and muscles, causing progressive weakness that typically starts in the legs. Some patients also develop memory problems, personality changes, or seizures from inflammation in the brain, or numbness and pain from nerve damage in the limbs. These neurological syndromes affect roughly 3 to 5 percent of SCLC patients overall.
How SCLC Is Diagnosed
SCLC is confirmed through a tissue biopsy. There is no blood test or scan that can definitively diagnose it on its own. The process usually starts with a CT scan of the chest, which reveals the tumor’s location and helps doctors decide how to obtain a tissue sample.
The biopsy method depends on where the tumor sits. Because SCLC typically grows near the central airways, a bronchoscopy (a thin camera threaded down the throat into the lungs) is a common approach. If the tumor or suspicious lymph nodes are deeper in the chest, doctors may use ultrasound-guided needles inserted through the airway wall or the esophagus to reach them. For tumors closer to the chest wall, a CT-guided needle biopsy through the skin may be used instead.
Limited Stage vs. Extensive Stage
SCLC uses a simpler staging system than most cancers, dividing into just two categories. Limited-stage means the cancer is confined to one side of the chest and nearby lymph nodes, an area small enough to be treated with a single radiation field. About one-third of patients are diagnosed at this stage.
Extensive-stage means the cancer has spread beyond that boundary, either to the other lung, to distant lymph nodes, or to other organs entirely. The majority of SCLC patients, roughly two-thirds, are already at this stage when first diagnosed. The brain, liver, bones, and adrenal glands are the most common sites of spread.
Treatment Approach
SCLC responds well to initial treatment, which is both its promise and its frustration. Chemotherapy combined with a platinum-based drug and etoposide has been the backbone of SCLC treatment for decades. For limited-stage disease, radiation to the chest is given alongside chemotherapy, which improves outcomes compared to chemotherapy alone.
A significant shift came in 2019 and 2020, when the FDA approved two immunotherapy drugs for use alongside chemotherapy in extensive-stage SCLC. These drugs, atezolizumab and durvalumab, work by blocking a protein that cancer cells use to hide from the immune system. Adding either one to standard chemotherapy was the first treatment advance to improve survival in extensive-stage SCLC in years, and the combination is now the standard first-line approach.
For patients who respond well to initial treatment, preventive radiation to the brain (prophylactic cranial irradiation) has been a standard recommendation since the late 1990s, particularly in limited-stage disease. The rationale is straightforward: SCLC has a high tendency to spread to the brain, and low-dose radiation can reduce that risk. More recently, doctors have debated whether regular brain MRI surveillance could replace preventive radiation in some patients, sparing them the cognitive side effects that can follow whole-brain treatment.
A newer targeted therapy called tarlatamab has shown promise for patients whose cancer returns after initial treatment. This drug works differently from chemotherapy or standard immunotherapy. It latches onto a protein called DLL3, which sits on the surface of SCLC cells in 85 to 94 percent of patients but is hidden inside normal cells. Tarlatamab physically bridges cancer cells and immune cells, forcing them into close contact so the immune system can destroy the cancer. In a phase 2 trial of 220 previously treated patients, 40 percent had their tumors shrink meaningfully, and among those who responded, 59 percent maintained that response for at least six months.
Survival Rates
SCLC has lower survival rates than most other cancers, reflecting how quickly it spreads and how often it returns after treatment. The five-year relative survival rate is 34 percent when the cancer is still localized, 20 percent when it has spread to nearby lymph nodes (regional), and 4 percent when it has spread to distant organs. These numbers are based on patients diagnosed between 2012 and 2018, so they don’t fully reflect the impact of newer immunotherapy combinations or targeted treatments.
The initial response to treatment is often dramatic. Most SCLC tumors shrink substantially with chemotherapy, and many patients feel significantly better within weeks of starting treatment. The challenge is that the cancer frequently comes back, often within a year, and becomes resistant to the drugs that initially worked. This pattern of strong initial response followed by resistant recurrence is the central problem in SCLC treatment and the reason survival rates remain low despite high response rates.